UK MHRA Medicines Brief
Headline
MHRA grants semaglutide a new licensed indication for metabolic-associated steatohepatitis with moderate-to-advanced fibrosis
Executive Summary
The MHRA approved semaglutide injection (Wegovy) on July 3, 2026 for the treatment of metabolic-associated steatohepatitis in adults with moderate-to-advanced liver fibrosis. This decision creates a new licensed indication for an already-approved GLP-1 receptor agonist, extending its regulatory scope into hepatology.
Bottom Line
The MHRA approval creates the first licensed pharmacological treatment for MASH with moderate-to-advanced fibrosis in the UK, establishing semaglutide as the regulatory benchmark for the indication. No NICE or Scottish Medicines Consortium reimbursement decision accompanies the authorisation, leaving NHS access pathways unresolved at the point of approval. Competing developers in the MASH pipeline now hold their programmes against a licensed standard rather than an unmet-need baseline.
Key Regulatory Signals
- New Indication Expands Prescribing Population: The approved indication covers adults with moderate-to-advanced liver fibrosis, a population distinct from the existing obesity and cardiovascular-risk indications. Healthcare systems and payers must now assess formulary positioning for a condition with no previously approved pharmacological treatment in the UK.
- Manufacturers and Competing Developers Face a Shifted Benchmark: Novo Nordisk holds the first MHRA-approved pharmacotherapy for MASH with fibrosis. Developers of competing MASH therapies, including those in late-stage trials, now face a licensed comparator against which their clinical programmes will be assessed by regulators and payers.
- Supply Chain and Allocation Pressure Intensifies: Semaglutide has faced documented supply constraints across its existing indications. A third approved indication adds demand pressure; manufacturers and dispensing organisations must account for a broader eligible population in supply planning.
- Reimbursement and Access Decisions Now Required: NICE and the Scottish Medicines Consortium have not yet issued appraisal decisions for this specific indication. NHS commissioning bodies face a gap period between marketing authorisation and funded access, requiring interim prescribing policy decisions.
Regulatory Delta
- No prior MHRA-approved pharmacotherapy existed for MASH with fibrosis. This is the first licensed treatment for the indication in the UK. - The approval moves semaglutide beyond its established metabolic indications into a hepatology setting — a structural departure from its prior licensed scope. - The EMA is conducting a parallel review of semaglutide for MASH. Whether the two agencies align or diverge will determine how market access develops across Europe.
Materiality Classification
HIGH — cross-region regulatory nexus (rule G)
Intelligence Outlook
Monitor NICE and the Scottish Medicines Consortium for technology appraisal initiation and reimbursement decisions for this indication, and monitor the EMA for a parallel opinion on the same semaglutide MASH indication.